Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies
Satoshi Motoya, Mamoru Watanabe, Hyo Jong Kim, Young Ho Kim, Dong Soo Han, Hirotoshi Yuasa, Junichi Tabira, Naoki Isogawa, Shoko Arai, Isao Kawaguchi, Toshifumi Hibi
Intest Res. 2018;16(2):233-245. Published online 2018 Apr 30 DOI: https://doi.org/10.5217/ir.2018.16.2.233
|
Citations to this article as recorded by
Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study
Seung Hwan Shin, Kyunghwan Oh, Sung Noh Hong, Jungbok Lee, Shin Ju Oh, Eun Soo Kim, Soo-Young Na, Sang-Bum Kang, Seong-Joon Koh, Ki Bae Bang, Sung-Ae Jung, Sung Hoon Jung, Kyeong Ok Kim, Sang Hyoung Park, Suk-Kyun Yang, Chang Hwan Choi, Byong Duk Ye
Therapeutic Advances in Gastroenterology.2023; 16: 175628482311541. CrossRef Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis
Jian Zeng, Zhong Wang, Xiao-Jun Yang
European Journal of Clinical Pharmacology.2022; 78(7): 1069. CrossRef Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef Safety and efficacy of long‐term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open
Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Hyo Jong Kim, Byong Duk Ye, Shoko Arai, Masato Hoshi, Hirotoshi Yuasa, Junichi Tabira, Shigeyuki Toyoizumi, Nanzhi Shi, Joon‐suk Woo, Toshifumi Hibi
Journal of Gastroenterology and Hepatology.2022; 37(10): 1884. CrossRef Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis
Brittany N. Palasik, Hongmei Wang
Journal of Pharmacy Practice.2021; 34(6): 913. CrossRef Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia
Shu-Chen Wei, Jose Sollano, Yee Tak Hui, Wei Yu, Paul V. Santos Estrella, Lyndon John Q. Llamado, Nana Koram
Expert Review of Gastroenterology & Hepatology.2021; 15(3): 275. CrossRef Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Toshifumi Hibi, Isao Kamae, Philippe Pinton, Lyann Ursos, Ryuichi Iwakiri, Greg Hather, Haridarshan Patel
Intestinal Research.2021; 19(1): 53. CrossRef Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
Intestinal Research.2021; 19(4): 386. CrossRef Post-inflammatory Abdominal Pain in Patients with Inflammatory Bowel Disease During Remission: A Comprehensive Review
Kazuya Takahashi, Iman Geelani Khwaja, Jocelyn Rachel Schreyer, David Bulmer, Madusha Peiris, Shuji Terai, Qasim Aziz
Crohn's & Colitis 360.2021;[Epub] CrossRef Multiple esophageal ulcers due to tofacitinib 10 mg twice daily for ulcerative colitis
Keiichi Tominaga, Mimari Kanazawa, Kazuhiro Takenaka, Takanao Tanaka, Takeshi Sugaya, Koh Fukushi, Yuka Takagi, Kazunori Nagashima, Keiichiro Abe, Naoya Izawa, Kohei Tsuchida, Makoto Iijima, Kenichi Goda, Hidetsugu Yamagishi, Atsushi Irisawa
Clinical Journal of Gastroenterology.2020; 13(3): 340. CrossRef Interleukin 23 and autoimmune diseases: current and possible future therapies
Ahmad Ismail Khaled Abdo, Gee Jun Tye
Inflammation Research.2020; 69(5): 463. CrossRef A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis
Keiichi Tominaga, Mimari Kanazawa, Takanao Tanaka, Shunsuke Kojimahara, Takeshi Sugaya, Shoko Watanabe, Akira Yamamiya, Yuichi Majima, Makoto Iijima, Kenichi Goda, Atsushi Irisawa
Medicina.2020; 56(11): 595. CrossRef Inhibidores de la vía de señalización JAK-STAT en el tratamiento de las enfermedades inmunomediadas
José M. Serra López-Matencio, Alberto Morell Baladrón, Santos Castañeda
Medicina Clínica.2019; 152(9): 353. CrossRef Interleukin-13: A promising therapeutic target for autoimmune disease
Yan-Mei Mao, Chan-Na Zhao, Jing Leng, Rui-Xue Leng, Dong-Qing Ye, Song Guo Zheng, Hai-Feng Pan
Cytokine & Growth Factor Reviews.2019; 45: 9. CrossRef JAK-STAT inhibitors for the treatment of immunomediated diseases
José M. Serra López-Matencio, Alberto Morell Baladrón, Santos Castañeda
Medicina Clínica (English Edition).2019; 152(9): 353. CrossRef Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
Ferdinando D’Amico, Tommaso Lorenzo Parigi, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Therapeutic Advances in Gastroenterology.2019; 12: 175628481984863. CrossRef Inhibitors of the Janus Kinases
Elisabetta Antonelli, Gabriele Torti, Gabrio Bassotti
Journal of Clinical Gastroenterology.2019; 53(9): 635. CrossRef Novel oral-targeted therapies for mucosal healing in ulcerative colitis
Elisabetta Antonelli, Vincenzo Villanacci, Gabrio Bassotti
World Journal of Gastroenterology.2018; 24(47): 5322. CrossRef
|